The therapeutic effects of the psychedelic compound psilocybin, derived from so-called “magic mushrooms” such as Psilocybe semilanceata, are now being more widely understood by medical science. One drawback of psilocybin-assisted therapeutic interventions is the requirement for the experience to be closely monitored and supported, due to the often-intense psychedelic and hallucinogenic experiences that can result from consumption. However, new efforts are trying to tease out what would be a minimal effective dose of psilocybin, one that would have beneficial effects on the brain whilst minimizing hallucinatory experiences